<DOC>
	<DOC>NCT01573598</DOC>
	<brief_summary>Safety and Efficacy of Vilazodone in Major Depressive Disorder</brief_summary>
	<brief_title>Safety and Efficacy of Vilazodone in Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Men and women, 1870 years of age Currently meet the DSMIVTR criteria for Major Depressive Disorder The patient's current major depressive episode must be at least 8 weeks and no longer than 18 months in duration Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control Patients with a history of meeting DSMIVTR criteria for: any manic, hypomanic or mixed episode, including bipolar disorder and substanceinduced manic, hypomanic, or mixed episode; any depressive episode with psychotic or catatonic features; panic disorder with or without agoraphobia; obsessivecompulsive disorder; Schizophrenia, schizoaffective, or other psychotic disorder; bulimia or anorexia nervosa; presence of borderline personality disorder or antisocial personality disorder; h. mental retardation, dementia, amnesia, or other cognitive disorders Patients who are considered a suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
</DOC>